Our GSDMBNT mRNA@LNP treatment recruited tumor-infiltrating CD4+ and CD8+ T cells, probably because the treatment initiates or reinitiates a self-sustaining cycle of cancer immunity after intratumoral TNF-α, IFN-γ, IL-1β, and IL-18 induction34, 35. This evidence concerns the gene IL1B and cancer.